1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A disease-causing single amino acid deletion in the coiled-coil domain of RAD50 impairs MRE11 complex functions in yeast and humans
    Journal Article

    Chansel-Da Cruz, M.; Hohl, M.; Ceppi, I.; Kermasson, L.; Maggiorella, L.; Modesti, M.; de Villartay, J. P.; Ileri, T.; Cejka, P.; Petrini, J. H. J.; more...
    Cell Reports (2020)

    Fulltext@MSK | Save
  • Cells under tension drive gastrulation
    Editorial

    Schwarz, C.; Hadjantonakis, A. K.
    Developmental Cell (2020)

    Fulltext@MSK | Save
  • Combined JAK2 and ERK1/2 kinase inhibition as a potent therapeutic approach in myeloproliferative neoplasms
    Meeting Abstract

    Brkic, S.; Stivala, S.; Santopolo, A.; Jungius, S.; Passweg, J. R.; Tsakiris, D.; Dirnhofer, S.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Therapeutic resistance to the novel JAK2 inhibitor CHZ868 in MPN is dependent on MEK-ERK activation and is targetable
    Meeting Abstract

    Szybinski, J.; Codilupi, T.; Wicki, A.; Yang, J. L.; Ghosh, N.; Passweg, J.; Tsakiris, D.; Levine, R. L.; Koche, R.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Dual genetic targeting of ERK1 and ERK2 reduces the fitness of the malignant clone in myeloproliferative neoplasm mice
    Meeting Abstract

    Stivala, S.; Brkic, S.; Santopolo, A.; Dirnhofer, S.; Passweg, J. R.; Tsakiris, D.; Neel, B.; Levine, R. L.; Meyer, S. C.
    Swiss Medical Weekly (2020)

    Fulltext@MSK | Save
  • Surveillance for early detection of neuroblastoma central nervous system relapse
    Meeting Abstract

    Modak, S.; Kushner, B.; Cheung, N. K.; Kramer, K.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Telemedicine blood pressure monitoring after anti-GD2 monoclonal antibody immunotherapy during the COVID-19 pandemic
    Meeting Abstract

    Glincher, R.; Cheung, N. K.; Kasper, C.; Scoppetuolo, L. A.; Modak, S.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • High-dose naxitamab (humanized-3F8) plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor (GM-CSF) for Resistant Osteomedullary Neuroblastoma: Major Responses and Outpatient Treatment in a Phase II Trial
    Meeting Abstract

    Kushner, B.; Modak, S.; Basu, E.; Roberts, S.; Mauguen, A.; Pandit-Taskar, N.; Cheung, N. K.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Favorable toxicity profile of bivalent GD2/GD3 neuroblastoma vaccine
    Meeting Abstract

    Modak, S.; Cheung, N. K.; Basu, E.; Roberts, S.; Kushner, B.
    Pediatric Blood and Cancer (2020)

    Fulltext@MSK | Save
  • Medulloblastoma utilize GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination
    Meeting Abstract

    Martirosian, V.; Deshpande, K.; Zhou, H.; Shen, K.; Stepanosyan, V.; Remsik, J.; Boire, A.; Isakov, D.; De Feyter, H.; Hurth, K.; more...
    Neuro-Oncology (2020)

    Fulltext@MSK | Save